What is claimed:

1. A pharmaceutical composition for administration by subcutaneous injection, the composition comprising

20% - 45% (w/w) of olanzapine;

35% - 65% (w/w) of an organic solvent comprising dimethyl sulfoxide, N-methyl-2-pyrrolidinone (NMP), or a combination thereof;

a diblock copolymer comprising polylactic acid and polyethylene glycol and having a number average molecular weight of 6 to 15 kg/mol and comprising 70% - 90% by weight (w/w) polylactic acid; and

a triblock copolymer comprising polylactic acid and polyethylene glycol and having a number average molecular weight of 6 to 19 kg/mol and comprising 80% - 90% by weight (w/w) polylactic acid;

and wherein the diblock copolymer and triblock copolymer together comprise 10% - 25% by weight (w/w) of the composition.

2. The pharmaceutical composition of claim 1, wherein the composition comprises 20%-24% by weight (w/w) olanzapine; or 22%-34% by weight (w/w) olanzapine; or 30%-32% by weight (w/w) olanzapine.

3. The pharmaceutical composition of claim 1 or claim 2, wherein the organic solvent is dimethyl sulfoxide (DMSO) or N-methyl-2-pyrrolidinone (NMP) or a mixture thereof.

4. The pharmaceutical composition of any one of the preceding claims, wherein the composition comprises 35% - 40% by weight (w/w) of the organic solvent or 50% - 55% by weight (w/w) of the organic solvent or 58% - 62% by weight (w/w) of the organic solvent.

5. The pharmaceutical composition of any one of the preceding claims, wherein the diblock copolymer comprises 75% - 84% by weight (w/w) polylactic acid or 73% - 77% by weight (w/w) polylactic acid or 84% to 88% by weight (w/w) polylactic acid; and/or wherein the diblock copolymer has a number average molecular weight of 6.5 to 13.5 kg/mol, optionally 7.0 to 13.5 kg/mol; and/or wherein the triblock copolymer comprises

85% - 88% by weight (w/w) polylactic acid; and/or wherein the triblock copolymer has a number average molecular weight of 6.0 to 13.0 kg/mol, optionally 7.0 to 12.0 kg/mol.

6. The pharmaceutical composition of any one of the preceding claims, wherein the composition comprises 10% - 17% by weight (w/w) of the diblock copolymer, optionally wherein the composition comprises 10% - 15% by weight (w/w) of the diblock copolymer; and/or wherein the composition comprises 3% - 5% by weight (w/w) of the triblock copolymer, optionally 3% - 4% by weight (w/w) of the triblock copolymer; and/or wherein the diblock copolymer and triblock copolymer together comprise 10 to 20% by weight (w/w), optionally 14 to 20% by weight (w/w) of the composition; and/or wherein the weight ratio of the diblock copolymer to the triblock copolymer is from 6:1 to 2:1, optionally about 4:1.

7. The pharmaceutical composition of any one of the preceding claims, wherein the composition contains from about 220 mg – about 340 mg of olanzapine per gram of composition.

8. A kit comprising:

a first container containing about 318 mg – about 950 mg of olanzapine; and

a second container containing about 0.73 – about 2.5 grams of a mixture of an organic solvent that is dimethyl sulfoxide (DMSO), N-methyl-2-pyrrolidinone (NMP), or a combination thereof, a diblock copolymer comprising polylactic acid and polyethylene glycol and having a number average molecular weight of 6 to 15 kg/mol and comprises 70% - 90% by weight (w/w) polylactic acid, and a triblock copolymer comprising polylactic acid and polyethylene glycol and having a number average molecular weight of 6 to 19 kg/mol and comprises 80% - 90% by weight (w/w) polylactic acid.

9. The kit of claim 8, wherein the first container containing the olanzapine is a glass vial and/or wherein the second container containing the mixture of an organic solvent, a diblock copolymer comprising polylactic acid and polyethylene glycol, and a triblock copolymer comprising polylactic acid and polyethylene glycol, is a syringe, optionally further comprising a needle, wherein the needle is capable of being fitted to the syringe,

optionally wherein the needle is a 21 gauge needle, optionally wherein the needle is 5/8 inches in length.

10. A method of preparing the composition of any one of claims 1-7, the method comprising adding a mixture of the organic solvent, the diblock copolymer comprising polylactic acid and polyethylene glycol, and the triblock copolymer comprising polylactic acid and polyethylene glycol, to solid olanzapine, optionally wherein the mixture of the organic solvent, the diblock copolymer comprising polylactic acid and polyethylene glycol, and the triblock copolymer comprising polylactic acid and polyethylene glycol is added by syringe to the solid olanzapine in a vial.

11. The kit of claim 8 or claim 9 or the method of claim 10, wherein the olanzapine has a particle size distribution characterized by a D(90) of from about 20 μm to about 37 μm, a particle size distribution characterized by a D(3,2) of from about 5.5 μm to about 7.5 μm, or a tapped density from about 0.35 g/ml to 0.44 g/ml, or any combination thereof, optionally wherein the olanzapine has a particle size distribution characterized by a D(90) of from about 24 μm to about 35 μm, optionally wherein the olanzapine has a particle size distribution characterized by a D(3,2) of from about 5.8 μm to about 7.0 μm.

12. The composition of any one of claims 1 to 7, the kit of claim 8 , 9 or 11, or the method of claim 10 or claim 11, wherein the olanzapine is polymorph form II.

13. Use of a composition of any one of claims 1-7 in the manufacture of a medicament for treating a disease or disorder that is schizophrenia, schizoaffective disorder, bipolar disorder, or depression, in a patient in need thereof, wherein the medicament is to be administered subcutaneously to the patient.

14. The use of claim 13, wherein the patient has a PANSS total score between 80 and 120, inclusive, at baseline (prior to randomization) with a score ≥4 on at least 2 of the following 4 items of the PANSS positive subscale: hallucinatory behavior, delusions, conceptual disorganization, or suspiciousness/persecution.

15. The use of claim 13 or claim 14, wherein the composition comprises 300 mg – 600 mg of olanzapine; or 300-350 mg, optionally 310-320 mg, of olanzapine; or comprises 400-450

mg, optionally 415-435 mg, of olanzapine; or 500-550 mg, optionally 520-540 mg, of olanzapine; and/or wherein the composition has a volume of about 0.5 – 1.8 mL; or has a volume of about 0.9 – 1.5 mL.

16. The use of any one of claims 13-15, wherein the composition is to be administered once per month or once per 28 ±5 days or once per 28 ±3 days or once per 28 days.

17. The use of any one of claims 13-16, wherein the dose-normalized ratio of AUC_{∞} after a single subcutaneous dose of the composition to the AUC_{tau} of oral olanzapine calculated for 28 days is between 0.97 - 1.29, or about 1.1.

18. The use of any one of claims 13-17, wherein administration of the composition to the patient by subcutaneous injection results in the patient having an olanzapine plasma C_{max} within 11-14 days after the administration.

19. The use of any one of claims 13-18, wherein administration of the composition to a patient by subcutaneous injection results in the patient having an olanzapine plasma C_{max} of less than 100 ng/mL, or less than 90 ng/mL, or less than 80 ng/mL, or less than 70 ng/mL, or less than 60 ng/mL, or less than 50 ng/mL, or less than 40 ng/mL after the first subcutaneous injection.

20. The use of any one of claims 13-19, wherein administration of the composition to a patient by subcutaneous injection results in the patient having an olanzapine plasma C_{max} of less than 100 ng/mL, or less than 90 ng/mL, or less than 80 ng/mL, or less than 70 ng/mL, or less than 60 ng/mL, or less than 50 ng/mL, or less than 40 ng/mL after the second subcutaneous injection.

21. The use of any one of claims 13-20, wherein administration of the composition to a patient by subcutaneous injection results in the patient having an olanzapine plasma concentration of at least 10 ng/mL, or at least 20 ng/mL for at least 21 days of the 30 days following the subcutaneous injection; and/or wherein administration of the composition to a patient by subcutaneous injection results in the patient having an olanzapine plasma concentration of at least 10 ng/mL, or at least 20 ng/mL for at least 30 days following the subcutaneous injection.

22. The use of any one of claims 13-21, wherein the treatment results in the patient having a lower score on the Positive and Negative Syndrome Scale (PANSS) than the patient had prior to receiving the treatment; and/or wherein the treatment results in the patient having a lower score on the Clinical Global Impression–Improvement (CGI-I) scale than the patient had prior to receiving the treatment; and/or wherein the treatment results in the patient having a lower score on the Clinical Global Impression– Severity of Illness Scale (CGI-S) scale than the patient had prior to receiving the treatment; and/or wherein the treatment results in the patient having a lower score on the Patient Global Impression-Improvement (PGI-I) than the patient had prior to receiving the treatment; and/or wherein treatment results in the patient having a higher score on the Personal and Social Performance Scale (PSP) than the patient had prior to receiving the treatment; and/or, wherein the treatment results in the patient having a lower score on the Schizophrenia Quality of Life Scale (SQLS) Revision 4 than the patient had prior to receiving the treatment; and/or wherein the treatment results in the patient having a lower score on the 3-Level EuroQol Five Dimensions Questionnaire (EQ-5D-3L) than the patient had prior to receiving the treatment; and/or wherein the treatment results in the patient having a D_2-receptor occupancy of 60-80%, optionally 65-80%, optionally 65-70%, as determined by positron emission tomography (PET).

23. Use of the composition of any one of claims 1-7 in the manufacture of a medicament for treating a disease or disorder that is schizophrenia, schizoaffective disorder, bipolar disorder, or depression, in a patient in need thereof, wherein the patient is to be switched from a daily oral olanzapine therapy to a therapy comprising once per month administration, wherein a daily oral olanzapine therapy is to be administered, after which no further oral olanzapine therapy is to be administered to the patient; and the next day the composition of any one of claims 1-7 is to be administered subcutaneously to the patient; thereby switching the patient from a daily oral olanzapine therapy to a therapy comprising administration of the composition of any one of claims 1-7 once per month.

24. Use of the composition of any one of claims 1-7 in the manufacture of a medicament for treating a disease or disorder that is schizophrenia, schizoaffective disorder, bipolar disorder, or depression, in a patient in need thereof, wherein the patient is to be switched from a long acting intramuscular injectable olanzapine formulation to the composition of

any one of claims 1-7, without the need for supplemental oral olanzapine therapy, wherein a final dose of the long acting intramuscularly injectable olanzapine formulation is to be administered to the patient; and at the next dosing, optionally one month after the preceding dose when the preceding dose is a once monthly dose, or optionally two weeks after the preceding dose when the preceding dose is a once every two-weeks dose, the composition of any one of claims 1-7 is to be administered subcutaneously to the patient; wherein a supplemental oral olanzapine therapy is not to be administered to the patient.

25. A pharmaceutical composition as defined in any one of claims 1-7 for use in therapy.

26. Use of the pharmaceutical composition of any one of claims 1-7 in the manufacture of a medicament for treating an olanzapine naïve patient, wherein an oral daily dose of 10 mg-20 mg olanzapine is to be administered to the patient for 2 consecutive days; the patient is to be assessed whether the patient tolerates the oral daily dose of olanzapine, and wherein the pharmaceutical composition of any one of claims 1-7 is to be administered subcutaneously to the patient if the patient is assessed as tolerating the daily dose of oral olanzapine.